PATENT CLAIM ANALYSIS

Application Number: 16326189
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "206100"]

Abstract:
The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

Claim (Index 19):
The pharmaceutical composition of  claim 18 , wherein the other therapeutic agent is amantadine, rimantadine, oseltamivir, zanamivir, peramivir, laninamivir, laninamivir octanoate hydrate, favipiravir, arbidol, ribavirin, stachyflin, ingavirin, fludase, CAS no. 1422050-75-6, JNJ-872, an influenza vaccine or a combination thereof.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 99.0
- Lexical Diversity: 1.48148
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16327335', '12905268', '14396754', '12728153', '15314932']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7854283412638621
- 35 USC 102 Novelty (BERT): 0.5760233205971446
- Combined Prediction Score: 0.7644878391971903
- Mean Citation Score: 375.97671
- Max Citation Score: 482.20844000000005
- Similarity Product: 406.5543387414551

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test